267 related articles for article (PubMed ID: 22127194)
21. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
[TBL] [Abstract][Full Text] [Related]
22. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
23. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.
Schaefer M; Sarkar R; Knop V; Effenberger S; Friebe A; Heinze L; Spengler U; Schlaepfer T; Reimer J; Buggisch P; Ockenga J; Link R; Rentrop M; Weidenbach H; Fromm G; Lieb K; Baumert TF; Heinz A; Discher T; Neumann K; Zeuzem S; Berg T
Ann Intern Med; 2012 Jul; 157(2):94-103. PubMed ID: 22801672
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
25. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
26. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
27. The onset of effect for escitalopram and its relevance for the clinical management of depression.
Wade A; Friis Andersen H
Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project.
Uher R; Perroud N; Ng MY; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Zagar T; Czerski PM; Jerman B; Larsen ER; Schulze TG; Zobel A; Cohen-Woods S; Pirlo K; Butler AW; Muglia P; Barnes MR; Lathrop M; Farmer A; Breen G; Aitchison KJ; Craig I; Lewis CM; McGuffin P
Am J Psychiatry; 2010 May; 167(5):555-64. PubMed ID: 20360315
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
Fantino B; Moore N; Verdoux H; Auray JP
Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
[TBL] [Abstract][Full Text] [Related]
31. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial.
Cook IA; Hunter AM; Gilmer WS; Iosifescu DV; Zisook S; Burgoyne KS; Howland RH; Trivedi MH; Jain R; Greenwald S; Leuchter AF
J Clin Psychiatry; 2013 Jan; 74(1):51-6. PubMed ID: 23419226
[TBL] [Abstract][Full Text] [Related]
32. Early response as predictor of final remission in elderly depressed patients.
Kok RM; van Baarsen C; Nolen WA; Heeren TJ
Int J Geriatr Psychiatry; 2009 Nov; 24(11):1299-303. PubMed ID: 19322797
[TBL] [Abstract][Full Text] [Related]
33. History of suicide attempts among patients with depression in the GENDEP project.
Perroud N; Uher R; Hauser J; Rietschel M; Henigsberg N; Placentino A; Kozel D; Maier W; Mors O; Souery D; Dmitrzak-Weglarz M; Jorgensen L; Kovacic Z; Giovannini C; Mendlewicz J; Zobel A; Strohmaier J; McGuffin P; Aitchison KJ; Farmer A
J Affect Disord; 2010 Jun; 123(1-3):131-7. PubMed ID: 19772940
[TBL] [Abstract][Full Text] [Related]
34. Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients.
Cattaneo A; Ferrari C; Uher R; Bocchio-Chiavetto L; Riva MA; ; Pariante CM
Int J Neuropsychopharmacol; 2016 Oct; 19(10):. PubMed ID: 27207917
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP.
Powell TR; Smith RG; Hackinger S; Schalkwyk LC; Uher R; McGuffin P; Mill J; Tansey KE
Transl Psychiatry; 2013 Sep; 3(9):e300. PubMed ID: 24002086
[TBL] [Abstract][Full Text] [Related]
36. [Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression].
Rajewska-Rager A; Skibińska M; Szczepankiewicz A; Kapelski P; Dmitrzak-Weglarz M; Leszczyńska-Rodziewicz A; Hauser J
Psychiatr Pol; 2008; 42(6):915-23. PubMed ID: 19441668
[TBL] [Abstract][Full Text] [Related]
37. First episode of major depressive disorder and vascular factors in coronary artery disease patients: Baseline characteristics and response to antidepressant treatment in the CREATE trial.
Habra ME; Baker B; Frasure-Smith N; Swenson JR; Koszycki D; Butler G; van Zyl LT; Lespérance F
J Psychosom Res; 2010 Aug; 69(2):133-41. PubMed ID: 20624511
[TBL] [Abstract][Full Text] [Related]
38. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report.
Fava M; Rush AJ; Wisniewski SR; Nierenberg AA; Alpert JE; McGrath PJ; Thase ME; Warden D; Biggs M; Luther JF; Niederehe G; Ritz L; Trivedi MH
Am J Psychiatry; 2006 Jul; 163(7):1161-72. PubMed ID: 16816220
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
40. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
